An interventional study of Resistance training and Resveratrol 500 mg oral once daily. in Sarcopenia and Anabolic Resistance, sponsored by Texas Tech University. Recruiting at 1 site in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by Texas Tech University · Not applicable, Interventional, and Prevention
The main goal of this study is to find out if supplementing with resveratrol improves skeletal muscle adaptations to strengthening exercise (resistance training or strength training) in adults age 60+, and to determine whether circulating vehicles of inter-organ communication (extracellular vesicles) and their cargo might help explain those responses. The investigators will also examine whether resveratrol supplementation improves blood vessel function and cognitive function (brain health) in response to strength training.
After screening and providing informed consent, participants (healthy older adults, age 60+, minimally active) will be familiarized with the procedures and undergo pre-testing. After pre-testing, participants will be assigned to supplement with resveratrol or placebo (double-blinded) daily while undergoing a strength training intervention. Strength training will be performed 3x/week for two 6-week blocks, and each visit will be supervised by a member of the study team. An additional week of testing will follow each of the two 6-week blocks.
1,329 studies on the registry are indexed under Sarcopenia; 420 are open to participants now.
This study's planned enrollment of 36 is below the median of 60 across 855 interventional studies indexed under Sarcopenia.
Browse Sarcopenia studies →Texas Tech University is the lead sponsor of 82 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to consume resveratrol (500 mg) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
Behavioral: Resistance training · Dietary Supplement: Resveratrol 500 mg oral once daily.
Participants will be randomized to consume placebo capsules (cellulose, visually identical to resveratrol capsules) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
Behavioral: Resistance training · Dietary Supplement: Placebo
After pre-testing, participants will perform full-body strength training three times per week for two 6-week blocks. The acute program variables (sets, repetitions, training frequency) will follow a non-linear periodized, progressive design consisting of muti-joint and single-joint exercises. Exercise stress will be varied by using different exercises and loads. The two training blocks will be separated by a mid-intervention testing week, allowing for the study team to monitor participants' progress, communicate progress to participants to promote adherence, and adjust target loads as appropriate for the second half of the intervention. An additional testing week will follow the second 6-week block.
Also known as: Strength training
Participants will be randomized to consume resveratrol (500 mg) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
Participants will be randomized to consume placebo capsules (cellulose, visually identical to resveratrol capsules) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
Circulating extracellular vesicle microRNA profile
Circulating extracellular vesicles will be isolated from plasma and their microRNA cargo will be sequenced.
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Muscle torque
Participants will be instructed to try and straighten their leg, against resistance, as forcefully as possible and maximal torque of the quadriceps assessed using a dynamometer.
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Muscle fatigability
Participants will perform 32 repetitions of knee extensions on a dynamometer and the change in torque from the beginning to the end will be used to indicate fatigability.
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Muscle strength
Participants will perform submaximal testing to assess strength on key exercises included in the strength training protocol.
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Appendicular skeletal muscle mass index
Assessed using dual-energy x-ray absorptiometry (DEXA)
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Waist-to-hip ratio
Waist and hip circumferences measured using measuring tape
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Vascular function
Flow-mediated dilation
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Cognitive function
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Grip strength
Handgrip dynamometry
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Lower body strength/endurance
Chair stand test (30 seconds)
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Gait speed
4-m walk test
Time frame: During pre-, mid-, and post-testing (each separated by about 6 weeks)
Plan to share: Yes — De-identified data from human participants (other than large-scale data) will be deposited into the TTU Dataverse with restricted access - by request only. Data will be linked only with a unique code. MicroRNA sequencing data will be deposited to the Gene Expression Omnibus (GEO). The following will be submitted to accompany data: Full study protocol Names and descriptions of data sets Annotated data collection forms Data dictionary Documentation of calculated variables Any changes made to the protocol over time Frozen datasets used for the primary publication, when applicable
Supporting information: Study protocol
Time frame: Dr. Danielle Levitt (PI) will deposit data into the appropriate repositories. Data upload will occur when publications associated with each data set are submitted and made public (where applicable) upon acceptance.
Access criteria: Human participants data (except large-scale data sets)- reasonable requests must be submitted to the TTU Dataverse. MicroRNA sequencing data will be available in large-scale output format with no identifiable information (unique code).
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Resveratrol
Texas Tech University